Rheumatoid arthritis is a systemic autoimmune rheumatic disorder of unknown etiology.
It is the most common form of inflammatory arthritis.
Patient usually complains of joint pain and/or swelling with morning stiffness that lasts for more than an hour.
Goals of treatment are clinical and radiological remission of disease and to reduce functional limitations and permanent joint damage.
More than half of rheumatoid arthritis (RA) patients achieving low disease activity on long-term methotrexate (MTX) remain flare-free following its withdrawal, as shown in a study. The use of a higher MTX dose to preserve low disease activity is predictive of disease flare after discontinuation.
The Janus kinase inhibitors tofacitinib 10 mg and peficitinib 150 mg prove to be the most effective regimens in the treatment of patients with refractory rheumatoid arthritis (RA) receiving methotrexate (MTX), without increasing the risk of serious adverse events, according to the results of a network meta-analysis.
The investigational interleukin (IL)-6 inhibitor olokizumab is effective in improving symptoms and physical function of patients with moderate-to-severe rheumatoid arthritis (RA) who are inadequately controlled with methotrexate (MTX), according to the CREDO-1 study presented at the EULAR 2020 Virtual Meeting.
New drug applications approved by US FDA as of 01 - 15 July 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Foods factor in the management of symptoms of rheumatoid arthritis (RA), and several dietary approaches help by removing staples that promote inflammation or by adding more of anti-inflammatory edibles and altering the gut microbiota, according to a team of researchers.
The investigational JAK1* inhibitor filgotinib was noninferior to adalimumab in reducing disease activity in patients with moderate-to-severe rheumatoid arthritis (RA) who had inadequate response to methotrexate (MTX-IR), according to the FINCH 1 study presented at EULAR 2020 Virtual Meeting.
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Advanced chronic kidney disease (CKD) associated with lupus nephritis (LN) does not necessarily lead to a need for dialysis, suggests a study, which shows majority of its patients (62 percent) not progressing over 10 year of follow-up on average.